Nicola Di Rienzo

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Francesca Romana Mauro, Andrea Visentin, Luca Laurenti, Susanna Gallo et autres

it (code pays fourni par la source)

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Adriano Venditti, Alfonso Piciocchi, Stefano Soddu, Marco Frigeni et autres

it (code pays fourni par la source)

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Roberto Latagliata, Benedetta Cambò, Anna Lina Piccioni, Vincenzo Federico et autres

it (code pays fourni par la source)

Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O‐CLL1‐GISL study

Massimo Gentile, Giovanna Cutrona, Laura Mosca, Serena Matis et autres

it (code pays fourni par la source)

RELATIONSHIP BETWEEN CYTOGENETIC ANOMALIES AND BIOMARKERS IN BINET STAGE A PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT DIAGNOSIS: PRELIMINARY RESULTS OF A PROSPECTIVE, MULTICENTER O-CLL1 GISL STUDY

Fabris, Giovanna Cutrona, Mattia Gentile, Serena Matis et autres

Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).

Roberto Latagliata, Massimo Breccia, Paola Fazi, Marco Vignetti et autres

it (code pays fourni par la source)

Measurement of soluble CD4 molecule in chronic lymphoproliferative disorders.

Pellegrino Musto, Maria Marta Minervini, Rosella Matera, Nicola Di Rienzo et autres

it (code pays fourni par la source)